Palbociclib is a potent and selective inhibitor of Cdk4, IC50 = 11 nM and Cdk6, IC50 = 16 nM.
Palbociclib inhibits phosphorylation of Rb protein and cell cycle progression through G1 in primary 5T33MM cells and sensitized these cells to killing by a proteasome inhibitor (bortezomib) in mouse models.
Induces autophagy and senescence in AGS gastric cancer cells and is clinically useful breast cancer agent. Cell cycle inhibitors boost tumor immunogenicity.
Research or further manufacturing use only, not for food or drug use.